Cosentyx vs otezla?

Cosentyx vs Otezla for psoriasis and psoriatic arthritis

Cosentyx and Otezla are both approved for plaque psoriasis and psoriatic arthritis, but they differ in mechanism, dosing, and side-effect profile. Cosentyx blocks interleukin-17A while Otezla raises cellular cAMP levels to reduce inflammation. Cosentyx comes as a monthly injection after initial loading doses; Otezla is taken twice daily as tablets.

How do side effects compare?

Cosentyx carries a higher risk of infections, including upper respiratory and candida infections, and requires tuberculosis screening before starting. Otezla often causes nausea, diarrhea, and weight loss, but does not require infection screening.

When does Cosentyx lose exclusivity?

Cosentyx holds patents until at least 2030, with some extensions pushing protection into the 2030s. Otezla’s core patents expired earlier, and biosimilar versions are already in development.

How does this drug compare with Keytruda?

Cosentyx and Otezla are not oncology agents like Keytruda, so they are not used for cancer treatment. They both belong to targeted therapies for immune-mediated diseases rather than checkpoint inhibitors.

Can biosimilars enter before patent expiry?

No. Biosimilars to Cosentyx are expected after its full patent term ends, while Otezla has already faced generic erosion in some markets.

Who makes Cosentyx and Otezla?

Cosentyx is made by Novartis. Otezla is owned by Amgen after its acquisition from Celgene.